60 Degrees Pharmaceuticals, Inc
60 Degrees Pharmaceuticals, Inc. (60P) is a U.S.-based specialty pharmaceutical company focused on infectious diseases, with a commercial malaria prevention product and a development pipeline targeting additional vector-borne, fungal, and viral indications. Its marketed product, Arakoda® (tafenoquine regimen), has been sold since late 2019 and is distributed primarily through third-party logistics and large pharmaceutical wholesalers, with significant rebates and discounts across the U.S. channel. The company also uses alternative supply routes (e.g., importing Kodatef with FDA approval during a packaging-related shortage) to maintain patient access. Beyond Arakoda, 60P is advancing programs based on tafenoquine, celgosivir, and botanical extracts from Australian chestnut trees, reflecting a strategy of lifecycle expansion and pipeline optionality in infectious disease prevention and treatment.
Fiscal year 2025 · change from previous year
Development 2023–2025
Business
Share of revenueU.S. and ex-U.S. sales of Arakoda malaria prevention via wholesalers/3PL and related channel programs.
Imported product supply used to serve patients during Arakoda packaging/availability disruptions.
Development of new products containing the Arakoda regimen of tafenoquine and other tafenoquine-based programs.
R&D programs using celgosivir for infectious disease applications, including viral diseases.
R&D programs using botanical extracts from Australian chestnut trees for infectious disease-related therapies.
Customers
60P’s near-term revenue is driven by sales of Arakoda to resellers and distribution partners rather than direct-to-patient sales. In the U.S., product flows through a third-party logistics (3PL) partner into large pharmaceutical distributors and then to pharmacies and dispensaries, with pharmacy benefit managers (PBMs) influencing patient access through formulary coverage and rebate-driven discounts. The company also uses specialty channels such as Infuserve America to supply patients, including during periods when standard commercial packaging was temporarily unavailable. Outside the U.S., the company sells via distributors in markets such as Australia and Europe, where profit-sharing arrangements can affect net economics per box sold. Customer concentration can be meaningful because a small number of distributors and channel partners can account for a large share of net product sales in a given period.
Purchase Arakoda for downstream distribution to pharmacies/dispensaries; economics include distributor rebates and channel fees.
Supplies patients when standard channels are constrained (e.g., packaging shortage) and can involve higher out-of-pocket/cash-pay dynamics.
Influence utilization through formulary placement and patient discounts; rebates (30%–41.25% cited) materially affect net revenue.
Buy product for local markets; certain foreign sales are subject to profit-sharing agreements affecting net realized revenue.
Strategy
60P’s strategy centers on expanding and stabilizing its Arakoda commercial franchise while using it as a platform for broader infectious-disease development. Near-term execution priorities include maintaining reliable supply and packaging formats in the commercial channel, as evidenced by the transition to a new 8-count bottle and temporary use of imported Kodatef to mitigate shortages. The company is also advancing a pipeline spanning vector-borne, fungal, and viral diseases using three stated product approaches: Arakoda-regimen products, tafenoquine-based products, and celgosivir/botanical-extract programs. Given limited liquidity runway disclosed in filings, financing strategy (ATM usage, offerings, warrants) remains intertwined with operating plans and the pace of clinical development. Overall, the company’s competitive position depends on channel access (PBMs/wholesalers), lifecycle management of tafenoquine-based assets, and disciplined capital allocation to pipeline programs.
Channel availability directly drives unit volumes and net sales; shortages reduce pharmacy/dispensary throughput.
Pipeline breadth provides additional shots on goal beyond a single marketed product and supports long-term value creation.
Management disclosed limited projected viability without additional raises; funding affects development pace and commercialization support.
Geography
The company is headquartered in the United States and generates most product revenue from U.S. commercial distribution of Arakoda. It also sells abroad, including through distributors in Australia and Europe, and notes that foreign sales can be subject to profit-sharing arrangements that change the net economics versus U.S. sales. Operationally, the business relies on a U.S.-centric supply chain model involving a 3PL partner, large U.S. distributors, and PBM-linked access pathways. Management notes that foreign operations are small relative to U.S. operations, which has made foreign currency translation effects minor in recent periods. Geographic mix matters primarily through channel structure (rebates/discounts) and the ability to maintain supply continuity across regions.
Risks
60P faces concentration and channel-pricing risk because Arakoda sales flow through a small number of distributors, a 3PL partner, and PBM arrangements where rebates can be large and variable, materially impacting net revenue. Operational execution risk is elevated given prior supply disruption tied to packaging validation delays, which reduced unit volumes and required mitigation via imported product and alternative distribution. As a small specialty pharma company, it also carries clinical and regulatory risk across its infectious-disease pipeline, where development timelines and outcomes are uncertain and may require additional capital. Financing and market-structure risks are prominent, including dilution from warrant exercises and the possibility of Nasdaq delisting if continued listing requirements (e.g., minimum bid price) are not met. Typical industry risks—manufacturing quality, product liability, competition from alternative prophylaxis/treatments, and inventory expiry/write-downs—can also affect profitability and continuity of supply.
Delisting would likely reduce liquidity and could increase cost of capital and limit investor access.
Exposure: Listing/market access
Pre-funded and Series A warrants could add substantial shares, diluting existing holders and pressuring share price.
Exposure: Equity capital structure / warrant overhang
A shortage of Arakoda 16-ct boxes reduced sales volume and required mitigation via Kodatef importation and new packaging.
Exposure: Operations / supply chain
Accounting
Judgemental itemsNet product revenue depends on timing of control transfer and estimates of rebates/discounts across 3PL, wholesalers, and PBMs.
Impact: Affects net sales, receivables/contract liabilities, and period-to-period comparability
Pharmaceutical inventory can expire; write-downs and manufacturing/serialization costs flow through cost of revenue.
Impact: Affects gross margin and can create quarter-to-quarter volatility
Similar listed companies
Publicly listed companies with a comparable business focus.
Cocrystal Pharma, Inc.
COCP · Pharmaceutical Preparations
Ironwood Pharmaceuticals, Inc
IRWD · Pharmaceutical Preparations
Ironwood Pharmaceuticals is a U.S.-based biopharmaceutical company focused on gastrointestinal therapies.
ARS Pharmaceuticals, Inc.
SPRY · Pharmaceutical Preparations
ARS Pharmaceuticals is a U.S.-based biopharmaceutical company built around neffy, a needle-free intranasal epinephrine product for the emergency treatment of…
Teva Pharmaceutical Industries Limited
TEVA · Pharmaceutical Preparations
Coya Therapeutics, Inc.
COYA · Pharmaceutical Preparations
Elite Pharmaceuticals Inc /NV/
ELTP · Pharmaceutical Preparations
Elite Pharmaceuticals, Inc.
Last updated: 24/09/2026